Evidence map›Paper›PMID 41755629›Full record

ArticleNucleic acids research2026

The role of the VirB ligand CTP in the molecular mechanism of transcriptional anti-silencing in Shigella flexneri.

Taylor M Gerson, Monika M A Karney, Helen J Wing

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Taylor M GersonSchool of Life Sciences, University of Nevada, Las Vegas, NV 89154-4004, United States.
Monika M A KarneySchool of Life Sciences, University of Nevada, Las Vegas, NV 89154-4004, United States.
Helen J WingSchool of Life Sciences, University of Nevada, Las Vegas, NV 89154-4004, United States.ORCID 0000-0003-0123-5568

Funding

Understanding transcriptional silencing & anti-silencing mechanisms in ShigellaR15AI090573 · NIAID · UNIVERSITY OF NEVADA LAS VEGAS · PI WING, HELEN J · 2010 to 2024
$2.3M
National Institute of Allergy and Infectious DiseasesNCRR NIH HHS P20 RR-016464NIH HHS R15 AI090573U.S. Department of Education GAANN fellowship P200A210055
6 · The paper itself

Abstract

In bacteria, nucleoid-structuring proteins bind and constrain DNA, often leading to transcriptional silencing. In Shigella spp., the histone-like nucleoid-structuring protein H-NS silences many genes on the large virulence plasmid. Upon a shift to human body temperature, VirB, a DNA-binding protein and key transcriptional regulator of the Shigella virulence cascade, is produced. VirB counteracts H-NS-mediated transcriptional silencing and belongs to a fast-evolving clade of the ParB superfamily. Like other ParB proteins, VirB binds the ligand CTP. While CTP is essential for the anti-silencing activity of VirB, the role of CTP in the mechanism of VirB-dependent anti-silencing has yet to be determined. This work shows that VirB does not require CTP for specific engagement of its DNA recognition site, but CTP is necessary for the formation of large VirB-DNA complexes, which likely form when VirB dimers adopt a sliding clamp conformation. Furthermore, CTP-binding mutants do not trigger a loss of negative supercoils from plasmid DNA, a VirB-dependent activity proposed to destabilize H-NS-DNA complexes. Together, our findings provide novel insight into the relationship between VirB, CTP, and DNA and reveal the role of the VirB ligand, CTP, in regulating Shigella virulence.

Indexed as

Bacterial ProteinsDNA-Binding ProteinsGene Expression Regulation, BacterialGene SilencingShigella flexneriTranscription, GeneticDNA, BacterialLigandsMutationPlasmidsBacterial ProteinsDNA, BacterialDNA-Binding ProteinsLigands

Identifiers

PMID41755629
PMCPMC12956337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.